AVANT BIO LLC
AVANT BIO LLC is a Seed, Series A, Series B and Series C+ fund in the US and Europe writing $100K–$50M checks into AI, Healthcare, life-sciences, techbio, diagnostics, biotechnology and pharmaceuticals.
- Stages
- Seed, Series A, Series B, Series C+
- Sectors
- AI, Healthcare, life-sciences, techbio, diagnostics, biotechnology, pharmaceuticals
- Check size
- $100K–$50M
- Invests in
- US-wide, Europe
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 2023
- Assets under management
- <$150M
- Website
- avant.bio
Thesis
AVANT BIO LLC, founded in 2023 and headquartered in New York City, is a growth equity firm with a strategic focus on the life sciences, technology bio (techbio), healthtech, and diagnostics sectors. The firm's investment thesis centers on therapeutic enabling technologies, biomanufacturing tools and automation, machine learning and AI applications, healthtech, techbio, and contract services. Key thematic areas include equitable access to therapies globally, speed and quality in drug discovery, new therapeutic modalities, robust manufacturing and supply chains, clinical trial access and diversity, and innovations in healthtech. The firm actively invests across North America and Europe. While AUM figures vary, one report indicates less than $150 million in assets under management as of March 31, 2026. The typical check size ranges from $100K to $5.0M, with a 'sweet spot' of $1.5 million for some investments, and potentially larger checks up to $50.0M for Principal/GP level investments.
Common questions
Does AVANT BIO LLC invest at the Seed stage?
Yes. AVANT BIO LLC lists Seed, Series A, Series B and Series C+ among the stages it invests in.
What check size does AVANT BIO LLC write?
AVANT BIO LLC writes $100K–$50M checks.
Where does AVANT BIO LLC invest?
AVANT BIO LLC invests in the US and Europe.